Impact of Diabetes Mellitus on Platelet Reactivity after Percutaneous Coronary Intervention: Data from 3 Different Platelet Function Assays

1,079 patients ≥ 18 years of age who had undergone drug-eluting stent (DES) implantation and were receiving maintenance dual antiplatelet treatment (DAPT) (75 mg/day clopidogrel and 100 mg aspirin). Single center in Busan, Korea. Key exclusions: hemodynamic instability, malignancies, active bleeding, contraindication to antiplatelet agents, concomitant use of warfarin or glycoprotein IIb/IIIa receptor blocker, platelet count < 80,000/mm3, hematocrit < 30%, AST/ALT ≥ 3 times upper normal limit, treatment with ticlopidine, prasugrel, ticagrelor, or dipyridamole, cardiac arrest or cerebrovascular injury within three months.

Diabetes Mellitus (exposure)

Platelet reactivity measured by 3 different platelet function assayssurrogate